Altus Pharmaceuticals Appoints Rebecca Dabora, Ph.D. Vice President Technical Operations and Manufacturing.CAMBRIDGE, Mass. -- Altus(R) Pharmaceuticals Inc., a leader in the development of novel protein therapies to treat chronic gastrointestinal and metabolic diseases, announced today that Rebecca Dabora, Ph.D. has been appointed Vice President of Technical Operations and Manufacturing. In this new position, Dr. Dabora will lead the technical operations and manufacturing activities for all of Altus' products, including TheraCLEC(TM), a novel enzyme replacement therapy Enzyme replacement therapy is a medical treatment replacing an enzyme in patients in whom that particular enzyme is deficient or absent. Usually this is done by giving the patient an intravenous (IV) infusion containing the enzyme. in Phase 2 clinical trials phase 2 clinical trial Phase 2 study. See Phase study. to treat malabsorption malabsorption /mal·ab·sorp·tion/ (mal?ab-sorp´shun) impaired intestinal absorption of nutrients. mal·ab·sorp·tion n. Defective or inadequate absorption of nutrients from the intestinal tract. as a result of pancreatic insufficiency pancreatic insufficiency A relative or absolute lack of pancreatic enzymes, a finding typical of cystic fibrosis. See Cystic fibrosis. . John Richard, Chairman of the Board for Altus said, "Becky comes to Altus with over fifteen years of experience in process and product development, as well as program management, in the biopharmaceutical industry. Her expertise in process development, program management, and all aspects of development and commercialization of biotechnological therapeutics will be a tremendous asset to Altus as we advance our pipeline of therapeutics for chronic gastrointestinal and metabolic diseases through clinical trials and into commercialization. We are excited to have Becky on our team." Before joining Altus, Dr. Dabora consulted with numerous biotechnology companies, where she developed and oversaw product development and manufacturing implementation plans to accelerate development and commercialization of new therapies. Prior to her consulting practice, Dr. Dabora served as Director, Process Development at Biogen, where she played an important role in the product and process development of several products including Amevive(R) and Avonex(R). Dr. Dabora began her career at Merck & Co., Inc. in the company's Technical Operations department Operations department See: Back office. operations department See back office. . Dr. Dabora received her Ph.D. in Biochemical Engineering from the Department of Applied Biological Sciences at the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, and her B.A. in Biochemistry from Bowdoin College. About Altus Pharmaceuticals Inc. Altus Pharmaceuticals is focused on developing and commercializing novel protein therapeutics for patients with chronic gastrointestinal and metabolic diseases. Altus' in-depth knowledge of protein crystallization Crystallization The formation of a solid from a solution, melt, vapor, or a different solid phase. Crystallization from solution is an important industrial operation because of the large number of materials marketed as crystalline particles. has resulted in a proprietary pipeline of orally delivered and injectable protein replacement products. As a company, Altus is committed to improving the quality of life of patients. More information about Altus and its clinical development programs can be found at www.altus.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion